ReviewFrontiers in immunology2026
IL-34 in neurological homeostasis and its multifaceted roles in central nervous system diseases.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-34 (IL-34), a ligand for the macrophage colony-stimulating factor receptor (CSF1R), plays an indispensable role in the development and homeostasis maintenance of the central nervous system (CNS). This review systematically outlines the core mechanisms by which the IL-34/CSF1R signaling axis regulates the development, colonization, and functional differentiation of CNS-resident immune cells-including microglia and border-associated macrophages (BAMs). It highlights its role in critical physiological processes such as synaptic pruning, neural circuit maturation, and maintenance of blood-brain barrier integrity. Beyond its physiological functions, IL-34 modulates diverse neurological disorders-such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, ischemic stroke-with context dependent outcomes. It can confer neuroprotective effects but also drive disease progression under different conditions, providing new insights into CNS homeostasis balance and the complexity of pathological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.